As a result, VEGF-A and its receptor VEGFR-2 have been considered as targets for various therapeutic approaches, not only for cancer, but also for other diseases such as diabetic retinopathy, diabetic macular edema and peripheral artery disease (PAD) [23, 24]. This evidence concerns the gene KDR and peripheral arterial disease.